Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

ClinicalTrials.gov ID: NCT02112838

Public ClinicalTrials.gov record NCT02112838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

Study identification

NCT ID
NCT02112838
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rigel Pharmaceuticals
Industry
Enrollment
76 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2014 (Type not available)
Primary completion
Mar 23, 2018 (Actual)
Completion
Nov 12, 2018 (Actual)
Last update posted
Jun 27, 2019

2014 – 2018

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Stanford University Medical Palo Alto California 94304 —
Nephrology Associates PC, University Hospital, Professional Center 1 Augusta Georgia 30901 —
Ohio State University Columbus Ohio 43210 —
Southeast Renal Research Institute Chattanooga Tennessee 37408 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02112838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2019 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02112838 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →